YOLFTbeta
Biomea Fusion Inc

Biomea Fusion Inc

BMEA · NASDAQ · Healthcare / Biotechnology

0.5822USD+0.02 (+3.47%)

Price History

Full chart

Market Stats

Previous Close0.5627
Open0.575
Day Range0.5401 – 0.60
52-Week Range0.8719 – 2.99
Volume563.88K
Market Cap107.73M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.19
Dividend Yield0.00%
Beta-0.24
50-Day Avg1.49
200-Day Avg1.42

About

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Michael J. M. Hitchcock Ph.D.
  • Employees37
  • Headquarters1599 Industrial Road, San Carlos, CA, United States, 94070, USA
  • Websitehttps://biomeafusion.com

Leadership

  • Dr. Michael J. M. Hitchcock Ph.D.Interim CEO & Director · b. 1950
  • Mr. Ramses M. ErdtmannCo-Founder, President, COO & Director · b. 1963
  • Mr. Heow TanChief Technical & Quality Officer · b. 1959
  • Caroline Perez- Dupont J.D.Senior Vice President of Legal
  • Dr. Thorsten Kirschberg Ph.D.Executive Vice President of Research · b. 1970
  • Dr. Stephan Morris M.D.Chief Development Officer
  • Mr. Ravi Upasani Ph.D.Executive Vice President of Intellectual Property

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue-132.00K953.00K1.26M4.20M1.75M1.41M
Gross Profit--132.00K-953.00K-1.26M-4.20M-1.75M-1.41M
Operating Expense-5.20M40.71M82.37M121.93M142.32M79.90M
Operating Income-1.20M-5.33M-41.67M-83.63M-126.14M-144.07M-81.31M
EBITDA-1.20M-5.19M-41.42M-82.94M-115.74M-136.68M-60.39M
Net Income-1.20M-5.32M-41.22M-80.02M-117.25M-138.43M-61.80M
R&D1.09M3.67M28.00M62.71M102.55M118.08M61.98M
Interest Expense00100.00K1.81M---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets265.00K62.53M185.71M129.31M199.93M79.94M58.57M
Total Liabilities286.00K57.36M6.92M20.77M30.69M28.36M29.02M
Total Equity-21.00K5.17M178.78M108.54M169.24M51.57M29.55M
Cash239.00K61.70M145.74M111.90M176.87M58.28M55.81M
Total Debt-259.00K2.85M2.29M10.30M8.77M1.59M
Net Debt-239.00K-61.44M-142.89M-109.61M-166.57M-49.51M-54.22M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.28M-4.46M-35.44M-62.42M-96.59M-119.89M-70.37M
Investing Cash Flow-51.00K-51.00K-33.35M27.34M-2.22M-362.00K-
Financing Cash Flow1.44M65.97M153.19M1.24M163.80M1.67M67.90M
Capital Expenditure51.00K51.00K3.17M1.03M3.37M362.00K0
Free Cash Flow-1.28M-4.51M-38.61M-63.45M-99.96M-120.26M-70.37M
FCF to OCF100.00%101.14%108.95%101.65%103.49%100.30%100.00%

Earnings

Report DateMay 27, 2021Aug 11, 2021Nov 3, 2021Feb 28, 2022May 16, 2022Aug 1, 2022Nov 7, 2022Mar 28, 2023May 2, 2023Jul 31, 2023Oct 30, 2023Jan 9, 2024May 2, 2024Jul 31, 2024Oct 29, 2024Mar 31, 2025May 5, 2025Aug 5, 2025Nov 4, 2025Mar 25, 2026May 11, 2026Aug 5, 2026Nov 3, 2026
EPS Estimate-0.14-0.20-0.40-0.45-0.53-0.61-0.64-0.81-0.81-0.88-0.83-0.85-0.93-1.09-0.91-0.91-0.60-0.51-0.29-0.22-0.19-0.21-0.21
EPS Actual-0.49-0.33-0.43-0.51-0.56-0.59-0.78-0.86-0.98-0.70-0.80-0.98-1.09-1.03-0.91-0.81-0.80-0.51-0.24-0.12-0.17-0.12-
Surprise-250.00%-65.00%-7.50%-13.33%-5.66%3.28%-21.88%-6.17%-20.99%20.45%3.61%-15.29%-17.20%5.50%0.00%11.18%-33.33%0.00%17.24%45.61%10.53%42.86%-
TimingAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap107.73M
Enterprise Value70.43M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book8.60
EPS-0.19
Book Value0.167
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-55.32M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-164.14%
Return on Assets-63.46%
Shares Outstanding72.30M
Shares Float67.63M
Beta-0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 9 analystsTarget 6.50
  • Strong Buy
    4
  • Buy
    3
  • Hold
    2

Ownership Breakdown

Institutions
40.02%
Insiders
7.15%
Retail / Other
52.83%

Top Institutional Holders

  • FMR Inc
    8.81M12.16%
  • Vanguard Capital Management, LLC
    2.60M3.58%
  • Aisling Capital Management LP
    2.05M2.83%
  • Renaissance Technologies Corp
    1.31M1.81%
  • Marshall Wace Asset Management Ltd
    1.20M1.65%
  • Fideuram - Intesa Sanpaolo Private Banking Spa
    723.18K1.00%
  • Mariner Wealth Advisors LLC
    654.58K0.90%
  • BlackRock Inc
    641.43K0.88%
  • Susquehanna International Group, LLP
    629.87K0.87%
  • Geode Capital Management, LLC
    548.19K0.76%
  • XTX Topco Ltd
    530.54K0.73%
  • UBS Group AG
    515.55K0.71%
  • Two Sigma Investments LLC
    384.46K0.53%
  • Morgan Stanley - Brokerage Accounts
    346.74K0.48%
  • Vanguard Fiduciary Trust Co
    336.12K0.46%

Top Fund Holders

  • Fidelity Growth Company Fund
    2.71M3.74%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.12M2.93%
  • Fidelity Growth Company K6
    910.50K1.26%
  • Fidelity Series Growth Company
    804.70K1.11%
  • Fidelity Select Biotechnology
    452.66K0.62%